49 results about "Orthotopic tumor" patented technology

The invention discloses a preparation method of magnetic induction hyperthermia embolism microspheres. The preparation method comprises the following steps of by taking a dissolved matter obtained bydissolving biodegradable high molecular polymers with low transition temperature and super paramagnetic Fe3O4 nano-particles into dichloromethane as an oil phase, Span 80 as a surfactant and an aqueous solution dissolved with polyvinyl alcohol (PVA) as an internal water phase, dropwise adding a water phase in the oil phase under the conditions with low temperature and high shearing to form primaryemulsion; placing the primary emulsion in a membrane emulsification instrument for membrane emulsification under the low temperature condition; forming multiple emulsion in a continuous phase of an external water phase PVA after the primary emulsion permeates a membrane, and performing low-temperature solidification to obtain the magnetic induction hyperthermia embolism microspheres which meet the demand for clinic size. The obtained microspheres are arbitrarily adjustable in size in a range from 100 microns to 1000 microns, can realize rabbit orthotopic liver cancer model embolism hyperthermia under guidance of iconography and have potential application in the interventional hyperthermia field of orthotopic tumors.

The invention belongs to the field of stem cells and biotechnology, and relates to a novel application of adipose-derived mesenchymal stem cells. Firstly, the invention provides a method for constructing adipose-derived mesenchymal stem cells carrying miR-122. In addition, the invention also discloses an application of the adipose-derived mesenchymal stem cells carrying miR-122 in the preparation of liver cancer chemosensitization preparations. The adipose-derived mesenchymal stem cells (AMSC) carrying miR-122 are used for preparing a chemosensitization agent and are combined with clinically conventional chemotherapeutic drugs so as to be applied to the chemotherapy of a liver cancer tumor-bearing mice model, so that the sensitivity of heterotopic or in-situ tumor tissues to the chemotherapeutic drugs can be obviously improved, the chemotherapy effect is enhanced, and the progress of the liver cancer is blocked. The dosage of the chemotherapeutic drugs can be reduced, and the chemotherapy side reaction is alleviated. The invention provides a technical support for preparing a novel liver cancer chemotherapy targeting sensitizer and a new method for the system chemotherapy of the liver cancer.

The invention discloses a preparation method and an application of a silicate long afterglow probe. Mesoporous silicon dioxide is used as a template, zinc nitrate, gallium nitrate, germanium nitrate,ytterbium nitrate, chromic nitrate and erbium nitrate are used as doped metal raw materials, the doped metal raw materials are dissolved in water and uniformly mixed, the mixture is dropwise added into the mesoporous silicon dioxide, roasting is performed at high temperature, and a pre-product is obtained after roasting is finished; then, functional modification is performed on the surface of thepre-product, and hydroxylation, amination and PEG modification are sequentially performed to obtain a modified pre-product; and finally, a photosensitizer silicon dichloride phthalocyanine is loaded to obtain the silicate long afterglow probe. The silicate long-afterglow probe has good biological safety, after caudal vein injection and under X-ray irradiation, a tumor area is effectively enriched,deep in-situ tumor imaging is achieved, in-situ tumor cells are seriously killed, and finally diagnosis and treatment integration of the silicate long-afterglow probe on deep tumors is achieved.

The invention discloses an application of bacteroides fragilis combined with an immune checkpoint inhibitor in treatment of skin tumors, in particular to a bacteroides fragilis ZY-312 with the preservation number of CGMCC No.10685, and the bacteroides fragilis ZY-312 is combined with a PD-1 inhibitor for use, so that the comprehensive curative effect of treating the skin tumors can be remarkably improved; the bacteroides fragilis can effectively prevent and treat generation, development, relapse and metastasis of melanoma by reducing the levels of proinflammatory factors IL-1, IL-6, IL-8 and VEGF, increasing migration of CD8 + effector T cells, reducing recruitment of Treg cells, reducing the weight of in-situ tumors and increasing the cancer inhibition rate, the harm of radiotherapy and chemotherapy to organisms is relieved, and the living quality of patients is improved.

The invention provides a medicine used for tumor treatment. The medicine comprises an ORFV attenuated strain. A virulence gene deletion strain of the ORFV is prepared through deletion of virulence genes including ORFV001-ORFV008, ORFV020, ORFV024, ORFV073, ORFV112-ORFV131 and ORFV134, and the virulence gene deletion strain is the ORFV attenuated strain. The ORFV attenuated strain is used for anti-tumor drugs, prevents tumor cell growth, promotes tumor cell death, prevents in-situ tumor growth, prevents tumor metastasis, and increases the proportion of immune cells in the tumor.

The invention belongs to the technical field of pharmaceutical preparations, and relates to a metformin-based nano drug delivery system and a preparation method thereof. The metformin-based nano drug delivery system is characterized in that a metformin amphiphilic derivative and a histone deacetylase inhibitor pro-DHA are mixed and self-assembled in water, triptolide is entrapped at the same time to form cationic micelles OPTs, the cationic micelles OPTs are used for preparing the metformin-based nano drug delivery system, HA is adsorbed on the surface through electrostatic adsorption, and a multi-drug mixed micelle is constructed. According to the mixed micelle, OA-Met (or metformin), pro-DHA and Trip are simultaneously delivered to in-situ tumor tissues in a targeted manner through high affinity of HA and tumor cell surface overexpression CD44, the three medicines play a synergistic effect through different action mechanisms to prevent EMT and tumor metastasis, growth of in-situ tumors is effectively inhibited, the lifetime is prolonged, and the mixed micelle has a good application prospect. The metastatic tumor treatment effect is improved, and good in-vivo safety is achieved.

The present invention provides an application of miRNA-203a-3p to development of pancreatic cancer inhibiting drugs. 1) a model for screening the pancreatic cancer metastasis inhibiting drugs is prepared; 2) a model for inhibiting pancreatic cancer metastasis is prepared; and a nucleotide sequence of the miRNA-203a-3p is as shown in SEQ ID NO:1. It is discovered that the miRNA-203a-3p is incapableof inhibiting pancreatic cancer cell proliferation and tumorigenesis, but can induce negative correlation expression of a pancreatic cancer cell metastasis related gene CERKL, and can be used for preparing the mouse model for inhibiting the pancreatic cancer metastasis; and the model can be applied to screening of the pancreatic carcinoma metastasis inhibiting drugs and is used as a tool for researching a mechanism of development from in-situ tumor (pancreatic cancer) to metastatic tumor (pancreatic cancer).

The invention discloses an application of Bacteroides fragilis and/or zwitterionic capsular polysaccharide thereof in preparation of a medicine for treating respiratory system tumors, the Bacteroides fragilis, especially the Bacteroides fragilis ZY-312 with the preservation number of CGMCC No.10685 and the zwitterionic capsular polysaccharide thereof, can be used for preparing medicines for treating respiratory system tumors by increasing the levels of anti-tumor factors IL-12 and IFN-gamma, and can be used for preparing medicines for treating respiratory system tumors. The traditional Chinese medicine composition can be used for inhibiting expression of a tumor promoting factor IL-1beta, promoting up-regulation of the proportion of infiltrated CD8 + CD45 + T cells in tumors, regulating the microenvironment of tumor tissues, reducing the weight of in-situ tumors and inhibiting the number of tumor metastases, can be used for effectively preventing and treating respiratory system tumors, can be independently used for cancer treatment, and also can be used for preventing and treating tumors. The traditional Chinese medicine composition can also be combined with other treatment means such as microorganisms, operations, radiotherapy and chemotherapy, so that the comprehensive curative effect is remarkably improved, the harm of radiotherapy and chemotherapy to organisms is relieved, occurrence, development, relapse and metastasis of respiratory system tumors are effectively prevented, and the living quality of patients is improved.

A use of recombinant ganoderma immunoregulatory protein (rLZ-8) in a preparation of a drug for treating melanoma is disclosed. By establishing experimental animal models of orthotopic tumors and metastatic tumors, an anti-tumor effect of the rLZ-8 is researched, which indicates that the rLZ-8 significantly inhibits a growth of the orthotopic tumors of the melanoma and a formation of metastases of the melanoma.

The invention provides a multi-functional antibody which is obtained through a genetic engineering technology, and synchronously has the biological effects of an IL-15/IL-15R(alpha) compound as targeted PD1. The invention further discloses a nucleic acid molecule for encoding the antibody, a recombinant vector containing the nucleic acid molecule, a recombinant cell containing the recombinant vector, as well as a preparation method and medical application of the multi-functional antibody. The multi-functional antibody can effectively solve the problems of drug resistance and disease recurrenceof single-target antibody drugs, as well as more effectively kill tumor cells and prolong survival times of in-situ tumor model animals at a reduced effective dose. Compared with an IL-15 or IL-15/IL-15 receptor compound, the multi-functional antibody is capable of prolonging serum half-life and improving tumor targeting property with toxic and side effects reduced.

The invention discloses a coronal gold-palladium nano heterogeneous material as well as a preparation method and application thereof, belongs to the technical field of photosensitive nano materials, and solves the technical problems that the photodynamic efficiency is low and metastatic cancer cells cannot be completely removed during photothermal/photodynamic synergistic treatment of cancers. Wherein the existence form of the gold element is a nanogold rod, the existence form of the palladium element is a bulge, the palladium bulge irregularly grows on the outer surface of the nanogold rod, and the mass ratio of the gold element to the palladium element is 1: (0.1-0.5). The prepared coronal gold-palladium nano heterogeneous material is used in drugs for killing in-situ tumor cells and inhibiting tumor recurrence and metastasis under a near-infrared light excitation condition. The coronal gold-palladium nano heterogeneous material prepared by the invention can effectively improve the photo-thermal and photodynamic efficiency of the material, kill in-situ tumor cells, induce generation of specific cytotoxic T lymphocytes, and effectively inhibit recurrence and metastasis of tumors.